Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Export

@article{citeulike:3744402, abstract = {Osteoclasts and osteoblasts dictate skeletal mass, structure, and strength via their respective roles in resorbing and forming bone. Bone remodeling is a spatially coordinated lifelong process whereby old bone is removed by osteoclasts and replaced by bone-forming osteoblasts. The refilling of resorption cavities is incomplete in many pathological states, which leads to a net loss of bone mass with each remodeling cycle. Postmenopausal osteoporosis and other conditions are associated with an increased rate of bone remodeling, which leads to accelerated bone loss and increased risk of fracture. Bone resorption is dependent on a cytokine known as RANKL (receptor activator of nuclear factor kappaB ligand), a TNF family member that is essential for osteoclast formation, activity, and survival in normal and pathological states of bone remodeling. The catabolic effects of RANKL are prevented by osteoprotegerin (OPG), a TNF receptor family member that binds RANKL and thereby prevents activation of its single cognate receptor called RANK. Osteoclast activity is likely to depend, at least in part, on the relative balance of RANKL and OPG. Studies in numerous animal models of bone disease show that RANKL inhibition leads to marked suppression of bone resorption and increases in cortical and cancellous bone volume, density, and strength. RANKL inhibitors also prevent focal bone loss that occurs in animal models of rheumatoid arthritis and bone metastasis. Clinical trials are exploring the effects of denosumab, a fully human anti-RANKL antibody, on bone loss in patients with osteoporosis, bone metastasis, myeloma, and rheumatoid arthritis.}, author = {Kearns, Ann E. and Khosla, Sundeep and Kostenuik, Paul J.}, citeulike-article-id = {3744402}, citeulike-linkout-0 = {http://dx.doi.org/10.1210/er.2007-0014}, citeulike-linkout-1 = {http://edrv.endojournals.org/cgi/content/abstract/29/2/155}, citeulike-linkout-2 = {http://view.ncbi.nlm.nih.gov/pubmed/18057140}, citeulike-linkout-3 = {http://www.hubmed.org/display.cgi?uids=18057140}, day = {1}, doi = {10.1210/er.2007-0014}, issn = {0163-769X}, journal = {Endocrine reviews}, keywords = {bmu, bone, opg, rankl, remodeling}, month = {April}, number = {2}, pages = {155--192}, posted-at = {2008-12-04 04:00:11}, priority = {2}, title = {Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.}, url = {http://dx.doi.org/10.1210/er.2007-0014}, volume = {29}, year = {2008} }

TY - JOUR ID - citeulike:3744402 L3 - citeulike-article-id:3744402 N2 - Osteoclasts and osteoblasts dictate skeletal mass, structure, and strength via their respective roles in resorbing and forming bone. Bone remodeling is a spatially coordinated lifelong process whereby old bone is removed by osteoclasts and replaced by bone-forming osteoblasts. The refilling of resorption cavities is incomplete in many pathological states, which leads to a net loss of bone mass with each remodeling cycle. Postmenopausal osteoporosis and other conditions are associated with an increased rate of bone remodeling, which leads to accelerated bone loss and increased risk of fracture. Bone resorption is dependent on a cytokine known as RANKL (receptor activator of nuclear factor kappaB ligand), a TNF family member that is essential for osteoclast formation, activity, and survival in normal and pathological states of bone remodeling. The catabolic effects of RANKL are prevented by osteoprotegerin (OPG), a TNF receptor family member that binds RANKL and thereby prevents activation of its single cognate receptor called RANK. Osteoclast activity is likely to depend, at least in part, on the relative balance of RANKL and OPG. Studies in numerous animal models of bone disease show that RANKL inhibition leads to marked suppression of bone resorption and increases in cortical and cancellous bone volume, density, and strength. RANKL inhibitors also prevent focal bone loss that occurs in animal models of rheumatoid arthritis and bone metastasis. Clinical trials are exploring the effects of denosumab, a fully human anti-RANKL antibody, on bone loss in patients with osteoporosis, bone metastasis, myeloma, and rheumatoid arthritis. IS - 2 JF - Endocrine reviews SN - 0163-769X EP - 192 TI - Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. VL - 29 SP - 155 KW - bmu KW - bone KW - opg KW - rankl KW - remodeling AU - Kearns, Ann AU - Khosla, Sundeep AU - Kostenuik, Paul PY - 2008/04/01/ UR - http://dx.doi.org/10.1210/er.2007-0014 ER -